Search Results - "Nishiki, Kazuaki"

Refine Results
  1. 1

    Successful treatment with dupilumab in mepolizumab-resistant allergic bronchopulmonary aspergillosis by Kawasaki, Yasutaka, Nishiki, Kazuaki, Ishizaki, Takeshi

    Published in Respiratory medicine case reports (01-01-2024)
    “…A 67-year-old woman with a history of poorly controlled asthma was admitted to our hospital with a persistent cough and abnormal chest radiographic findings…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Ruptured pseudoaneurysm of the thoracic aorta mimicking lung cancer: A case report by Takahara, Yutaka, Nishiki, Kazuaki, Nakase, Keisuke, Mizuno, Shiro

    Published in Thoracic cancer (01-03-2021)
    “…A 70‐year‐old woman was admitted to a local hospital with a five‐day history of back pain. She had been referred to our hospital after an abnormal chest shadow…”
    Get full text
    Journal Article
  4. 4

    Acquired pulmonary arteriovenous malformation associated with bronchiectasis: a case report by Kawasaki, Yasutaka, Nojiri, Masafumi, Oikawa, Taku, Nishiki, Kazuaki, Nakase, Keisuke, Takahara, Yutaka, Mizuno, Shiro

    Published in Journal of medical case reports (21-01-2022)
    “…Pulmonary arteriovenous malformations are mostly caused by congenitally abnormal shunts between pulmonary arteries and pulmonary veins. A 74-year-old Japanese…”
    Get full text
    Journal Article
  5. 5

    Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment by Takahara, Yutaka, Abe, Ryudai, Nagae, Sumito, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Nishiki, Kazuaki, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku

    Published in Thoracic cancer (01-12-2023)
    “…Background Several options for second‐line therapy are available for patients with advanced non‐small cell lung cancer (NSCLC); however, the optimal therapy…”
    Get full text
    Journal Article
  6. 6

    Disease control in patients with non‐small cell lung cancer using pemetrexed: Investigating the best treatment strategy by Takahara, Yutaka, Abe, Ryudai, Sumito, Nagae, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Nishiki, Kazuaki, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku

    Published in Thoracic cancer (01-04-2024)
    “…Background Pemetrexed (PEM) is the primary chemotherapy for non‐small cell lung cancer (NSCLC), showing potential for long‐term disease stability in certain…”
    Get full text
    Journal Article
  7. 7

    Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer by Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Fujimoto, Yuki, Oikawa, Taku, Mizuno, Shiro

    Published in Thoracic cancer (01-02-2022)
    “…Background The efficacy of rechallenge with immune checkpoint inhibitors (ICIs) in non‐small cell lung cancer (NSCLC) patients has not yet been fully…”
    Get full text
    Journal Article
  8. 8

    Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50 by Takahara, Yutaka, Abe, Ryudai, Sumito, Nagae, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Nishiki, Kazuaki, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku

    Published in Thoracic cancer (01-09-2023)
    “…Immune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non-small cell lung cancer (NSCLC) patients with programmed…”
    Get full text
    Journal Article
  9. 9

    Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer by Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku, Mizuno, Shiro

    Published in Thoracic cancer (01-05-2023)
    “…Background Amrubicin (AMR) has become the standard of care for post‐relapse small cell lung cancer (SCLC). It has also been reported to achieve long‐term…”
    Get full text
    Journal Article
  10. 10

    Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy by Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku, Mizuno, Shiro

    Published in Thoracic cancer (01-12-2022)
    “…Background The clinical characteristics and risk factors for cancer recurrence have not been well evaluated regarding early recurrence in patients with…”
    Get full text
    Journal Article
  11. 11

    Primary pulmonary T-cell lymphoma with lung adenocarcinoma: a case report by Takahara, Yutaka, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Ueda, Yoshimichi, Mizuno, Shiro

    Published in Journal of medical case reports (30-06-2019)
    “…Primary pulmonary T-cell lymphoma is an extremely rare disease that is characterized by neoplastic proliferation of T-cell lymphocytes in the lung. An…”
    Get full text
    Journal Article
  12. 12

    Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series by Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku, Mizuno, Shiro

    Published in Cancer reports (01-01-2023)
    “…Background Large cell neuroendocrine tumors of the lung (LCNEC) are rare. Chemotherapy with the small cell lung carcinoma (SCLC) regimen is the most…”
    Get full text
    Journal Article
  13. 13

    Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows by Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Fujimoto, Yuki, Oikawa, Taku, Mizuno, Shiro

    Published in Thoracic cancer (01-10-2021)
    “…Background The risk of cancer treatment‐related acute exacerbation (AE) in patients with lung cancer and mild interstitial lung disease (ILD) on imaging,…”
    Get full text
    Journal Article
  14. 14

    Exogenous gene transfer of Rab38 small GTPase ameliorates aberrant lung surfactant homeostasis in Ruby rats by Osanai, Kazuhiro, Nakase, Keisuke, Sakuma, Takashi, Nishiki, Kazuaki, Nojiri, Masafumi, Kato, Ryo, Saito, Masatoshi, Fujimoto, Yuki, Mizuno, Shiro, Toga, Hirohisa

    Published in Respiratory research (24-04-2017)
    “…Background Rab38 small GTPase regulates intracellular transport in melanocytes and alveolar type II epithelial cells. Ruby rats carrying Rab38 and other gene…”
    Get full text
    Journal Article
  15. 15

    A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis by Takahara, Yutaka, Yamamura, Kouichi, Matsuura, Saki, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Rieko, Fujimoto, Yuki, Oikawa, Taku, Osanai, Kazuhiro, Ueda, Yoshimichi, Mizuno, Shiro

    Published in Respiratory medicine case reports (01-01-2020)
    “…A 53-year-old woman was referred to our hospital for detailed examination of abnormal chest shadows recognized on CT imaging. Transbronchial lung biopsy of a…”
    Get full text
    Journal Article
  16. 16

    Prognostic value of the serum creatinine/cystatin C ratio in patients with chronic obstructive pulmonary disease by Kawasaki, Yasutaka, Nishiki, Kazuaki, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Oikawa, Taku, Ishizaki, Takeshi, Toga, Hirohisa, Mizuno, Shiro

    Published in Respiratory investigation (01-01-2024)
    “…Sarcopenia, characterized by skeletal muscle atrophy and physical inactivity, is a manifestation of chronic obstructive pulmonary disease (COPD) and is…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    ADRB2 gene polymorphism and emphysema heterogeneity can modulate bronchodilator response in patients with emphysema by Nojiri, Masafumi, Mizuno, Shiro, Nishiki, Kazuaki, Kato, Ryo, Nakagawa, Ken, Oikawa, Taku, Iguchi, Masaharu, Osanai, Kazuhiro, Ishizaki, Takeshi, Toga, Hirohisa

    Published in Pulmonary pharmacology & therapeutics (01-02-2018)
    “…Genetic variation in the β2-adrenergic receptor (ADRB2) gene has been thought to have an important role in the differential response to β2-agonist therapy for…”
    Get full text
    Journal Article
  20. 20